Landmark UK Trial Launches to Revolutionize Prostate Cancer Screening
The first men have been tested as part of the Transform trial, a landmark UK study poised to reshape the future of prostate cancer screening. Funded by Prostate Cancer UK and the National Institute for Health and Care Research (NIHR), the £42 million trial aims to deliver results and potentially influence screening practices within as little as two years.
Experts hope Transform will inform future population-wide prostate cancer screening for men by identifying the most effective combination of tests, including genetic tests and fast MRI scans .
The trial’s launch comes as the UK National Screening Committee (UKNSC) publishes its final guidance this week on prostate cancer screening. A draft recommendation last year advised against population-wide screening using the prostate specific antigen (PSA) test, citing concerns that it “is likely to cause more harm than good.”
The committee currently recommends screening only for men with BRCA1 and BRCA2 genetic mutations – which significantly increase their risk of prostate cancer – every two years, between the ages of 45 and 61.
Controversial Recommendations and the Need for Modern Evidence
Health Secretary Wes Streeting expressed surprise at the UKNSC’s draft recommendation, emphasizing that any final decision must be “based on science and evidence, not on politics.”
The debate surrounding the PSA test centers on its reliability. Experts note that a high PSA level doesn’t always indicate cancer, while some men with cancer have normal PSA results. A positive result can lead to unnecessary treatment for slow-growing or harmless tumors, potentially causing side effects like incontinence and erectile dysfunction.
However, proponents of wider testing argue that current evidence supports its use and urge a reconsideration of the screening approach. The UKNSC has committed to reviewing new evidence generated by the Transform trial.
Transform Trial: A Patient’s Perspective
One of the first participants in the Transform trial is Jaroslaw Galik, 55, from London. He and other men attended an InHealth community diagnostic center in Ealing, west London, undergoing a combination of PSA blood tests, fast MRI scans, and genetic spit tests.
“I’d heard a bit about prostate cancer over the years and had always thought I should probably speak to my GP, but I never actually got round to doing anything about it,” said Mr. Galik. “There isn’t that routine screening programme, so it just wasn’t something that felt urgent. When the letter about Transform came through, I realised this was a straightforward way to check my own risk while likewise contributing to something bigger.”
He added, “To think that just by taking a couple of tests I could be helping to finally get to screening and save thousands of lives is incredible.”
Addressing Health Disparities and Trial Stages
Laura Kerby, chief executive of Prostate Cancer UK, stated, “Men across the country are crying out for a screening programme and we’re committed to building a future where every man gets that chance. That is why we have driven the development of Transform and funded the £42 million programme, alongside the NIHR.”
The trial aims to gather more data relating to Black men, who are at double the risk of developing and dying from prostate cancer, with a goal of including one in ten participants from this community. The NIHR is working closely with Black community leaders and organizations to ensure meaningful participation in the research .
The initial phase of the trial will compare new screening techniques against current NHS methods. The next stage will evaluate the most promising methods in a larger group of up to 300,000 men.
NIHR’s Commitment to Prevention
Professor Lucy Chappell, chief scientific adviser at the Department of Health and chief executive officer of the NIHR, emphasized the significance of the trial: “Transform aims to tackle one of the biggest killers as part of the shift from sickness to prevention. Importantly, the trial will focus on men at highest risk, particularly Black men – a group who face double the risk of developing and dying from prostate cancer.”
More than 52,000 men are diagnosed with prostate cancer in the UK each year, and sadly, 12,000 men die of it .